Parth Rali United States

Dr. Rali currently serves as Director of the Temple University Health System Pulmonary Embolism Response Team (PERT) Program, Chair of the TUHS Anticoagulation Stewardship Committee, and Chair of the National PERT Consortium Protocol Committee. He is the incoming Vice Chair of the CHEST Pulmonary Vascular and Cardiovascular Network, Vice Chair of the Asia Pacific Respiratory Society Pulmonary Circulation Assembly, and a Board Member of The PERT Consortium®. In addition, he serves on the Pulmonary Leadership Board of the American Lung Association in Philadelphia and is Director of the PCCM Fellowship Social Media and Wellness Committee. His work has focused on advancing systems of care for pulmonary embolism and strengthening multidisciplinary collaboration through PERT programs.
Job Title
Professor, Thoracic Medicine and Surgery
Faculty / Department / Division
Department of Thoracic Medicine and Surgery
Institution / Organisation
Lewis Katz School of Medicine, Temple University Hospital

20 November 2026, Friday

Time Session
18:30
21:00
Parth Rali Speaker United States
Function Room 7, Ground Mezzanine Floor

21 November 2026, Saturday

Time Session
11:00
12:30
Chai Chan Sin Chairperson Malaysia
Fatimah Azmah Mohammad Chairperson Malaysia
  • Parth Rali Speaker United States
  • Luis Jara-Palomares Speaker Spain
    Chronic thromboembolic pulmonary hypertension (CTEPH) is a potentially treatable cause of pulmonary hypertension characterised by persistent organised pulmonary arterial obstruction and secondary microvascular remodelling. Despite advances in management, delayed recognition and unequal access to expert care remain important challenges. This presentation reviews the contemporary diagnostic and therapeutic pathway, integrating guideline recommendations with evidence from clinical trials and international registries. Persistent dyspnoea or exercise limitation after pulmonary embolism should prompt structured assessment, while the absence of a recognised embolic event does not exclude CTEPH. Ventilation–perfusion imaging, anatomical assessment and right heart catheterisation provide complementary information for diagnosis and treatment planning. Multidisciplinary evaluation is central to selecting pulmonary endarterectomy, balloon pulmonary angioplasty and medical therapy. Lifelong therapeutic anticoagulation remains essential, although uncertainty persists regarding the optimal anticoagulant for patients without antiphospholipid syndrome. Symptomatic chronic thromboembolic pulmonary disease without resting pulmonary hypertension requires careful symptom attribution and individualised treatment decisions. Future developments include circulating biomarkers, novel therapies targeting vascular remodelling and artificial intelligence for earlier detection, complication prediction and phenotyping. Multimodal models integrating clinical, biochemical and imaging data could support diagnostic testing and referral decisions, but require external validation and prospective demonstration of clinical benefit. Earlier recognition, timely expert referral and individualised multimodal care remain the priorities for improving outcomes.
  • Q&A
Ballroom 3, Lower Ground Floor